Literature DB >> 8763275

Tenascin in human papillomavirus associated lesions of the uterine cervix.

R Pöllänen1, Y Soini, S Vuopala, E Läärä, V P Lehto.   

Abstract

The immunohistochemical expression of tenascin was studied in 80 morphologically diagnosed condylomas and cervical intraepithelial neoplasia (CIN) lesions. The results were compared with the human papillomavirus (HPV) DNA subtype, which was determined by HPV dot blot and in situ hybridisation. Tenascin mRNA synthesis was also determined in 10 selected cases by in situ hybridisation. No statistically significant association was found between tenascin expression and the degree of dysplasia or the HPV subtype. There was, however, a strong correlation between the extent of tenascin immunoreactivity and the degree of inflammation. Synthesis of tenascin mRNA was detected in basal keratinocytes and in fibroblasts by in situ hybridisation. The lack of association between the grade of CIN and tenascin expression precludes its use as a marker of premalignancy in CIN.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763275      PMCID: PMC500551          DOI: 10.1136/jcp.49.6.521

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  8 in total

1.  Simultaneous expression of 70 kilodalton type IV collagenase and type IV collagen alpha 1 (IV) chain genes by cells of early human placenta and gestational endometrium.

Authors:  H Autio-Harmainen; T Hurskainen; K Niskasaari; M Höyhtyä; K Tryggvason
Journal:  Lab Invest       Date:  1992-08       Impact factor: 5.662

2.  Oncogenic association of specific human papillomavirus types with cervical neoplasia.

Authors:  A T Lorincz; G F Temple; R J Kurman; A B Jenson; W D Lancaster
Journal:  J Natl Cancer Inst       Date:  1987-10       Impact factor: 13.506

3.  Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis.

Authors:  R Chiquet-Ehrismann; E J Mackie; C A Pearson; T Sakakura
Journal:  Cell       Date:  1986-10-10       Impact factor: 41.582

Review 4.  Oncotrophoblast gene expression: placental alkaline phosphatase.

Authors:  W H Fishman
Journal:  Adv Cancer Res       Date:  1987       Impact factor: 6.242

5.  Human tenascin: primary structure, pre-mRNA splicing patterns and localization of the epitopes recognized by two monoclonal antibodies.

Authors:  A Siri; B Carnemolla; M Saginati; A Leprini; G Casari; F Baralle; L Zardi
Journal:  Nucleic Acids Res       Date:  1991-02-11       Impact factor: 16.971

Review 6.  Cytotactin: a morphoregulatory molecule and a target for regulation by homeobox gene products.

Authors:  G M Edelman; F S Jones
Journal:  Trends Biochem Sci       Date:  1992-06       Impact factor: 13.807

7.  Enhanced tenascin expression in cervical and vulvar koilocytotic lesions.

Authors:  O Tiitta; T Wahlström; J Paavonen; A Linnala; S Sharma; V E Gould; I Virtanen
Journal:  Am J Pathol       Date:  1992-10       Impact factor: 4.307

8.  Epithelial induction of stromal tenascin in the mouse mammary gland: from embryogenesis to carcinogenesis.

Authors:  Y Inaguma; M Kusakabe; E J Mackie; C A Pearson; R Chiquet-Ehrismann; T Sakakura
Journal:  Dev Biol       Date:  1988-08       Impact factor: 3.582

  8 in total
  3 in total

Review 1.  Tenascin-C and integrins in cancer.

Authors:  Toshimichi Yoshida; Tatsuya Akatsuka; Kyoko Imanaka-Yoshida
Journal:  Cell Adh Migr       Date:  2015       Impact factor: 3.405

Review 2.  The Roles of Matricellular Proteins in Oncogenic Virus-Induced Cancers and Their Potential Utilities as Therapeutic Targets.

Authors:  Naoyoshi Maeda; Katsumi Maenaka
Journal:  Int J Mol Sci       Date:  2017-10-21       Impact factor: 5.923

3.  Prediction of lymphovascular space invasion using a combination of tenascin-C, cox-2, and PET/CT radiomics in patients with early-stage cervical squamous cell carcinoma.

Authors:  Xiaoran Li; Chen Xu; Yang Yu; Yan Guo; Hongzan Sun
Journal:  BMC Cancer       Date:  2021-07-28       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.